Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that, because of slow-to-change treatment strategies and a low burden of disease in developed countries, interest in trials of novel agents for invasive cervical cancer has been low.

"The development of effective therapies for cervical cancer, historically treated with surgery and radiotherapy, has been hindered by drug developers' lack of enthusiasm for this small market," said Joanne Graham, Ph.D., analyst at Decision Resources. "In addition, since the availability of screening programs, the incidence of advanced disease in many industrialized countries has declined."

The new Pharmacor study entitled Cervical Cancer also finds that therapeutic human papillomavirus-directed vaccines on the horizon could spare women surgery and preserve fertility. Clinicians are optimistic that vaccines will be successful; such treatments could have a major impact on the cervical cancer market because these agents are likely to have a high cost. However, it will be more than 10 years before this effect is felt.

About Cervical Cancer

Cervical cancer is the second most common cancer in women worldwide. The successful uptake of screening programs and a better understanding of the role of human papillomavirus in the disease have resulted in a dramatic decline in the incidence of cervical cancer in many countries. However, a future increase in incidence of cervical cancer may occur due to increased immigration from unscreened populations and increased sexual activity in young adults.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Aggressive Marketing Campaigns Coupled with Emerging Agents' More Manageable Side Effects Will Aid the Migraine Prophylaxis Drug Market

View Now